Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors - PubMed (original) (raw)
Clinical Trial
. 2008 Dec 1;14(23):7917-23.
doi: 10.1158/1078-0432.CCR-08-1223.
Christopher Jones, Mark Middleton, Richard Wilson, Jeffrey Evans, Anna Olsen, Nicola Curtin, Alan Boddy, Peter McHugh, David Newell, Adrian Harris, Patrick Johnson, Heidi Steinfeldt, Raz Dewji, Diane Wang, Lesley Robson, Hilary Calvert
Affiliations
- PMID: 19047122
- PMCID: PMC2652879
- DOI: 10.1158/1078-0432.CCR-08-1223
Clinical Trial
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
Ruth Plummer et al. Clin Cancer Res. 2008.
Abstract
Purpose: One mechanism of tumor resistance to cytotoxic therapy is repair of damaged DNA. Poly(ADP-ribose) polymerase (PARP)-1 is a nuclear enzyme involved in base excision repair, one of the five major repair pathways. PARP inhibitors are emerging as a new class of agents that can potentiate chemotherapy and radiotherapy. The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy.
Experimental design: Initially, patients with solid tumors received escalating doses of AG014699 with 100 mg/m2/d temozolomide x 5 every 28 days to establish the PARP inhibitory dose (PID). Subsequently, AG014699 dose was fixed at PID and temozolomide escalated to maximum tolerated dose or 200 mg/m2 in metastatic melanoma patients whose tumors were biopsied. AG014699 and temozolomide pharmacokinetics, PARP activity, DNA strand single-strand breaks, response, and toxicity were evaluated.
Results: Thirty-three patients were enrolled. PARP inhibition was seen at all doses; PID was 12 mg/m2 based on 74% to 97% inhibition of peripheral blood lymphocyte PARP activity. Recommended doses were 12 mg/m2 AG014699 and 200 mg/m2 temozolomide. Mean tumor PARP inhibition at 5 h was 92% (range, 46-97%). No toxicity attributable to AG014699 alone was observed. AG014699 showed linear pharmacokinetics with no interaction with temozolomide. All patients treated at PID showed increases in DNA single-strand breaks and encouraging evidence of activity was seen.
Conclusions: The combination of AG014699 and temozolomide is well tolerated, pharmacodynamic assessments showing proof of principle of the mode of action of this new class of agents.
Figures
Figure 1
Structure of AG014699, phosphate salt of tricyclic indole PARP-inhibitor with Ki < 5 nM
Figure 2
Pharmacodynamic effects of AG014699. a, b, c Summary of PBL and tumour PARP inhibition measured using PARP activity immunoassay. a and b representative plots from day -7, 1 and 4 of the first treatment cycle from patients treated with 2 mg/m2 (a) and 12 mg/m2 (b) c Summarised data from tumour biopsies taken 5 hours after the first dose of AG014699 at the dose levels indicated. Data expressed as percentage activity compared to pre-treatment biopsy in the same individual d,. DNA damage in peripheral blood mononuclear cells by cohort. Blood was sampled on day 4 of the first treatment cycle before (hashed), 4h after (white) and 24h after (black) temozolomide dosing. Each reading is the mean of up to 6 patients.
Similar articles
- Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ, Clifford SC. Daniel RA, et al. Clin Cancer Res. 2009 Feb 15;15(4):1241-9. doi: 10.1158/1078-0432.CCR-08-1095. Epub 2009 Jan 27. Clin Cancer Res. 2009. PMID: 19174487 - Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?
Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, Kyle S, Robson T, Shaw C, Hirst DG, Curtin NJ, Williams KJ. Ali M, et al. Clin Cancer Res. 2009 Oct 1;15(19):6106-12. doi: 10.1158/1078-0432.CCR-09-0398. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789326 Free PMC article. - Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ. Plummer ER, et al. Clin Cancer Res. 2005 May 1;11(9):3402-9. doi: 10.1158/1078-0432.CCR-04-2353. Clin Cancer Res. 2005. PMID: 15867241 Clinical Trial. - PARP inhibitors for cancer therapy.
Curtin NJ. Curtin NJ. Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. doi: 10.1017/S146239940500904X. Expert Rev Mol Med. 2005. PMID: 15836799 Review. - PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
del Rivero J, Kohn EC. del Rivero J, et al. Oncology (Williston Park). 2017 Apr 15;31(4):265-73. Oncology (Williston Park). 2017. PMID: 28412778 Review.
Cited by
- Advances in DNA damage response inhibitors in colorectal cancer therapy.
Yu Y, Jia H, Zhang T, Zhang W. Yu Y, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Jan 25;56(1):15-22. doi: 10.3724/abbs.2023278. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38115743 Free PMC article. Review. - Evolution of the Development of PARP Inhibitors.
Plummer R. Plummer R. Cancer Treat Res. 2023;186:1-11. doi: 10.1007/978-3-031-30065-3_1. Cancer Treat Res. 2023. PMID: 37978127 - Poly(ADP-ribose) Polyremase-1 (PARP-1) Inhibition: A Promising Therapeutic Strategy for ETS-Expressing Tumours.
Legrand AJ, Choul-Li S, Villeret V, Aumercier M. Legrand AJ, et al. Int J Mol Sci. 2023 Aug 30;24(17):13454. doi: 10.3390/ijms241713454. Int J Mol Sci. 2023. PMID: 37686260 Free PMC article. Review. - A New Opportunity for "Old" Molecules: Targeting PARP1 Activity through a Non-Enzymatic Mechanism.
Iglesias P, Seoane M, Golán-Cancela I, Fraga M, Arce VM, Costoya JA. Iglesias P, et al. Int J Mol Sci. 2023 May 16;24(10):8849. doi: 10.3390/ijms24108849. Int J Mol Sci. 2023. PMID: 37240195 Free PMC article. - Benzimidazole and its derivatives as cancer therapeutics: The potential role from traditional to precision medicine.
Lee YT, Tan YJ, Oon CE. Lee YT, et al. Acta Pharm Sin B. 2023 Feb;13(2):478-497. doi: 10.1016/j.apsb.2022.09.010. Epub 2022 Sep 21. Acta Pharm Sin B. 2023. PMID: 36873180 Free PMC article. Review.
References
- Hoeijmakers JH. Genone maintenance mechanisms for preventing cancer. Nature. 2001;411:360–74. - PubMed
- Heinen CD, Schmutte C, Fishel R. DNA repair and tumorigenesis: lessons from hereditary cancer syndromes. Cancer Biol Ther. 2002;1:477–85. - PubMed
- Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell. 2004;6:539–45. - PubMed
- Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med. 2005;111:127–48. - PubMed
- Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev. 2005;31:603–17. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous